Premium Fertility Chain 'Haoyunbang' Secures New Round of Funding, Upholding MDT and Integrated Care Model to Accelerate Pregnancy Outcomes

“Haoyunbang,” a chain of specialized reproductive health clinics focusing on infertility, has completed a new round of financing. This round was led by Zero2IPO Asset Management, with continued participation from existing shareholder Plagrand. The funds will be used to enhance medical capabilities and accelerate the expansion of its specialized clinic network in the Chinese market. Previously, the company received consecutive investments from multiple institutions, including Boxing Capital, Gene Capital, Green Pine Capital, New Vision Ventures, and Puhua Capital.

The reproductive health sector is a field of significant attention. In China, the number of patients suffering from infertility exceeds 40 to 50 million, and the prevalence rate continues to rise due to multiple factors such as environmental influences, work-related stress, and delayed childbearing age, driving sustained growth in the overall market size for reproductive healthcare. The listing of Jinxin Medical has drawn greater interest from capital investors and entrepreneurs to this market; however, exploration and development within the industry remain challenging due to constraints such as IVF licensing requirements and intensifying operational competition.

Since its establishment in 2014, Haoyunbang has been deeply engaged in this field. Over the past six years, through the exploration and experimentation of various business models and pathways, the entire team has gained a deeper understanding of the reproductive health industry. Leveraging the advantages of its internet platform, Haoyunbang remains committed to establishing outpatient clinics as its core operational foundation, gradually creating a closed-loop system for conversion and services between its online platform and offline clinics. To date, Haoyunbang has established specialized reproductive health outpatient clinics in Beijing, Guangzhou, Jinan, Wuhan, and other cities, and has independently built a reproductive center in Thailand.

Haoyunbang’s online platform holds distinct advantages, standing as the largest domestic platform in the niche sector of infertility treatment. It serves over 11 million users and, through its physician-facing interface, connects with more than 10,000 specialists in the field of reproductive medicine. In December 2018, when Haoyunbang secured a financing round led by Boxing Capital, the company chose not to allocate funds toward expanding physical clinics. Instead, it concentrated its efforts on building and enhancing medical capabilities, recruiting a more prominent and professional team of medical partners, and continuously refining its foundational medical services and quality control systems.

Founder Huang Sen introduced: Infertility is a unique chronic condition, and its diagnosis and treatment process can be emotionally draining and arduous. We hope that Haoyunbang can clearly deliver two key values. The first value is to truly solve the problem by helping clients achieve pregnancy—more accurately, to help them conceive more quickly while ensuring safety and health. The second value is companionship; we aim to provide warm, empathetic services that accompany our clients through this extraordinary journey of personal growth and healing.

Returning to the core needs and requirements of our clients, we design the services and processes we offer around two key dimensions: success rates and patient experience. Over the past two years, both highly complex cases and less challenging ones have increasingly bolstered our confidence. Through our dedicated efforts, patients with difficult infertility issues can achieve pregnancy, while those with less complicated conditions can conceive more quickly. We are gaining a clearer understanding that our steadfast adherence to the Multidisciplinary Team (MDT) medical philosophy and our integrated approach of management combined with treatment genuinely benefit our clients. Compared to overcrowded large-scale reproductive centers, we believe our model delivers higher-quality medical services and a superior patient experience. By leveraging a chain of medical institutions, we provide convenient access to professional, high-quality basic medical care. Meanwhile, through internet-based solutions, we optimize and manage the diagnosis and treatment journey for infertility patients, facilitating orderly collaboration among top experts across various subspecialties. This represents an innovative attempt at a new healthcare model, and we are confident that it will help more patients, serving as a valuable exploration in the advancement of specialized reproductive medicine.

As the lead investor in this funding round, Zero2IPO Asset Management specializes in providing strategic industrial layout and mid-to-long-term asset management investment services to listed companies and family enterprises. It currently manages dozens of strategic funds for listed companies and family funds, with assets under management exceeding RMB 20 billion. The funds under its management primarily focus on sectors such as healthcare and wellness, consumption upgrades, intelligent manufacturing, culture and entertainment, and education, with an emphasis on investing in growth-stage projects.

From the perspective of Zero2IPO Asset Management, among the more than 500 licensed IVF centers currently operating in China, only a few dozen are running at full capacity. Meanwhile, a substantial demand for assisted reproductive services and fertility preservation remains unmet, creating a structural imbalance within the industry. “We recognize three core competencies of the Haoyunbang team: first, the ability to acquire traffic and efficiently convert and distribute it, which forms the foundation for addressing this structural imbalance; second, the capability to provide high-quality offline medical services, which distinguishes them from mere channel intermediaries; and third, the ability to rapidly replicate and expand individual clinics, which ensures scalable growth. Zero2IPO Asset Management is pleased to join and support Haoyunbang’s rapid development, and we look forward to working with the team to safeguard and support human reproductive freedom through medical and biotechnological advancements.”